Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Enterprise Value (2016 - 2025)

Zevra Therapeutics' Enterprise Value history spans 11 years, with the latest figure at -$191.0 million for Q4 2025.

  • For Q4 2025, Enterprise Value fell 174.85% year-over-year to -$191.0 million; the TTM value through Dec 2025 reached -$191.0 million, down 174.85%, while the annual FY2025 figure was -$191.0 million, 174.85% down from the prior year.
  • Enterprise Value reached -$191.0 million in Q4 2025 per ZVRA's latest filing, up from -$199.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$40.2 million in Q1 2023 to a low of -$202.6 million in Q2 2025.
  • Average Enterprise Value over 5 years is -$98.9 million, with a median of -$82.7 million recorded in 2022.
  • Peak YoY movement for Enterprise Value: plummeted 3122.28% in 2021, then skyrocketed 60.44% in 2023.
  • A 5-year view of Enterprise Value shows it stood at -$112.3 million in 2021, then increased by 26.69% to -$82.4 million in 2022, then increased by 17.76% to -$67.7 million in 2023, then dropped by 2.6% to -$69.5 million in 2024, then plummeted by 174.85% to -$191.0 million in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Enterprise Value are -$191.0 million (Q4 2025), -$199.5 million (Q3 2025), and -$202.6 million (Q2 2025).